EU orphan‑drug panel backs Ascendis’ TransCon CNP for achondroplasia
The European Medicines Agency’s Committee for Orphan Medicinal Products issued a positive opinion recommending that the orphan‑drug status for Ascendis Pharma’s once‑weekly TransCon CNP (navepegritide) be maintained in the EU. If the European Commission confirms the opinion, the therapy would receive ten years of market exclusivity. Ascendis expects the Commission’s final decision in the fourth quarter of 2026 and plans a German launch in the first quarter of 2027. The drug was already approved by the U.S. FDA in February 2026.
Why it matters
The potential ten‑year exclusivity could significantly boost Ascendis’ revenue stream once the product is launched in Europe, as noted by the company’s press release. Analysts at TipRanks have raised their price target to $273, reflecting expectations of strong earnings contribution from the EU market.
Key facts
- 1The EMA’s Committee for Orphan Medicinal Products gave a positive opinion to keep orphan status for TransCon CNP (navepegritide) as a treatment for achondroplasia in children. investing.com
- 2If the European Commission adopts the opinion, the drug will obtain ten years of orphan‑drug market exclusivity. investing.com
- 3Ascendis expects the European Commission’s final decision during Q4 2026. investing.com
- 4The company plans its first EU launch of TransCon CNP under the brand name YUVIWELL in Germany in Q1 2027. investing.com
- 5TransCon CNP received U.S. FDA approval in February 2026 for pediatric achondroplasia. investing.com
- 6TipRanks analysts assign a Buy rating with a $273.00 price target to Ascendis stock. tipranks.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.